A detailed history of Green Alpha Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 818 shares of VRTX stock, worth $380,010. This represents 0.31% of its overall portfolio holdings.

Number of Shares
818
Previous 887 7.78%
Holding current value
$380,010
Previous $415,000 8.43%
% of portfolio
0.31%
Previous 0.34%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$460.0 - $505.78 $31,740 - $34,898
-69 Reduced 7.78%
818 $380,000
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $46,351 - $57,292
-118 Reduced 11.74%
887 $415,000
Q1 2024

Apr 09, 2024

SELL
$407.69 - $446.08 $3,261 - $3,568
-8 Reduced 0.79%
1,005 $420,000
Q4 2023

Jan 04, 2024

SELL
$343.0 - $410.68 $61,397 - $73,511
-179 Reduced 15.02%
1,013 $412,000
Q3 2023

Oct 10, 2023

SELL
$338.18 - $362.46 $220,155 - $235,961
-651 Reduced 35.32%
1,192 $414,000
Q2 2023

Jul 06, 2023

BUY
$314.42 - $351.91 $79,233 - $88,681
252 Added 15.84%
1,843 $648,000
Q1 2023

Apr 06, 2023

SELL
$283.23 - $323.1 $12,745 - $14,539
-45 Reduced 2.75%
1,591 $501,000
Q4 2022

Jan 12, 2023

SELL
$285.76 - $321.48 $4,572 - $5,143
-16 Reduced 0.97%
1,636 $0
Q3 2022

Oct 14, 2022

BUY
$273.83 - $305.53 $1,642 - $1,833
6 Added 0.36%
1,652 $478,000
Q2 2022

Jul 08, 2022

SELL
$234.96 - $292.55 $279,367 - $347,841
-1,189 Reduced 41.94%
1,646 $464,000
Q1 2022

Apr 19, 2022

BUY
$221.42 - $260.97 $24,134 - $28,445
109 Added 4.0%
2,835 $740,000
Q4 2021

Jan 12, 2022

BUY
$177.01 - $223.45 $11,151 - $14,077
63 Added 2.37%
2,726 $599,000
Q3 2021

Oct 12, 2021

BUY
$181.39 - $202.99 $48,068 - $53,792
265 Added 11.05%
2,663 $483,000
Q2 2021

Jul 22, 2021

BUY
$187.49 - $221.1 $89,807 - $105,906
479 Added 24.96%
2,398 $484,000
Q1 2021

Jul 22, 2021

BUY
$207.02 - $241.31 $397,271 - $463,073
1,919 New
1,919 $412,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Green Alpha Advisors, LLC Portfolio

Follow Green Alpha Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.